<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02242149</url>
  </required_header>
  <id_info>
    <org_study_id>30194914.3.0000.5257</org_study_id>
    <nct_id>NCT02242149</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects</brief_title>
  <acronym>DGCLFT2DM</acronym>
  <official_title>Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidade Federal do Rio de Janeiro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rio de Janeiro State Research Supporting Foundation (FAPERJ)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidade Federal do Rio de Janeiro</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to test the hypothesis that in uncontrolled type 2 diabetic adults
      treatment with diacerein will improve glycemic control and will reduce liver fat within a 24
      month period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Recently, knowledge about diacerhein, an anthraquinone drug with powerful
      anti-inflammatory properties, revealed that this drug improves insulin sensitivity, mediated
      by the reversal of chronic subclinical inflammation. Amongst the numerous pathogenetic
      factors, oxidative stress and apoptosis of hepatocytes initiate many inflammatory processes
      and are involved in the progression of Non alcoholic fatty liver disease.

      Aims:The aim is to evaluate the effect of treatment with diacerein in improvement of glycemic
      parameters (mean glycated hemoglobin, fasting blood sugar) and reduction of liver fat
      fraction.

      Methods:Two-hundred patients will be randomly allocated either to treatment with diacerein
      plus their usual therapeutic regimen or to placebo for 24 months. Clinic, laboratory
      evaluation (including glycated hemoglobin, fasting blood sugar, creatinine, ferritin,
      aspartate aminotransferase (AST), alanine aminotransferase (ALT), g-glutamyl transpeptidase,
      alkaline phosphatase, bilirubin, albumin, prothrombin time, platelet count, total
      cholesterol, high-density and low-density lipoprotein cholesterol and triglycerides and
      urinary albumin excretion rate no 24-hour urine collection) will be performed before and
      every 3 months until the end of study. Pro-Inflammatory cytokines, adiponectin and
      cytokeratin-18 were measured before, at 12 months and at the end of study. Liver fat fraction
      measurement using controlled attenuation parameter (CAP) by transient elastography.
      (Fibroscan) will be performed before and after the 12 and 24-month treatment, with the
      observers blinded to the allocation group.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 14, 2014</start_date>
  <completion_date type="Actual">January 31, 2018</completion_date>
  <primary_completion_date type="Actual">January 31, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evidence of improvement in glycemic control and improvement in liver steatosis</measure>
    <time_frame>Within 12 and 24 months</time_frame>
    <description>Reduction of mean glycated hemoglobin (≥ 1%) and reduction of liver fat fraction as measured by transient elastography (≥ 20%)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement of microalbuminuria</measure>
    <time_frame>Within 24 months</time_frame>
    <description>Reduction of albumin excretion rate on 24-hour urine collection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of adipocytokines and cytokeratin-18</measure>
    <time_frame>Within 24 months</time_frame>
    <description>Elevation of high molecular weight adiponectin and reduction of the apoptotic by-product cytokeratin (CK)-18</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Non-alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diacerein</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Diacerein</intervention_name>
    <description>All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.</description>
    <arm_group_label>Diacerein</arm_group_label>
    <other_name>Artrodar</other_name>
    <other_name>Artifit</other_name>
    <other_name>Acert</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic Diacerein</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes.

          -  Presence of liver steatosis diagnosed by ultrasound or transient elastography
             (Fibroscan®)

          -  Age 30-75 years.

          -  HbA1c 7.5- 9.5 for at least 8 weeks prior to screening.

          -  Stable diabetes therapeutic regimen consisting of either diet, oral hypoglycemic
             agents with or without insulin for 8 weeks prior to randomization.

        Exclusion Criteria:

          -  Body mass index &gt; 40 kg/m2

          -  Serum creatinine ≥180mmol/L or estimated glomerular filtration rate &lt; 30 ml/min.

          -  Presence of any serious concomitant disease, such as a pulmonary disease or malignant
             disorders.

          -  Current daily alcohol ingestion ≥20 g.

          -  Hepatotoxic drugs.

          -  Presence of other chronic liver disease other than nonalcoholic fatty liver disease,
             including hepatitis B virus and hepatitis C virus infection, hemochromatosis, Wilson's
             disease, alfa-1 antitrypsin deficiency, autoimmune hepatitis.

          -  Women seeking pregnancy.

          -  Current use or previous use within 6 months of vitamin E or pioglitazone
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil F Salles, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Rio de Janeiro</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Program of Arterial Hypertension, University Hospital Clementino Fraga Filho</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 14, 2014</study_first_submitted>
  <study_first_submitted_qc>September 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 16, 2014</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidade Federal do Rio de Janeiro</investigator_affiliation>
    <investigator_full_name>Gil Fernando da Costa Mendes de Salles, PhD</investigator_full_name>
    <investigator_title>Full Professor, Faculty of Medicine</investigator_title>
  </responsible_party>
  <keyword>Fat liver</keyword>
  <keyword>Diabetes</keyword>
  <keyword>Diacerein</keyword>
  <keyword>Transient elastography</keyword>
  <keyword>Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diacetylrhein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

